These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 22984125

  • 21. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T.
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [Abstract] [Full Text] [Related]

  • 22. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
    Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE.
    Blood; 2009 Sep 10; 114(11):2273-9. PubMed ID: 19597184
    [Abstract] [Full Text] [Related]

  • 23. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
    Gebauer N, Bernard V, Feller AC, Merz H.
    Anticancer Res; 2013 Nov 10; 33(11):4771-8. PubMed ID: 24222112
    [Abstract] [Full Text] [Related]

  • 24. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
    Maeshima AM, Taniguchi H, Nomoto J, Miyamoto K, Fukuhara S, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.
    Hum Pathol; 2013 Nov 10; 44(11):2529-35. PubMed ID: 23916290
    [Abstract] [Full Text] [Related]

  • 25. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 26. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
    Johnson SM, Umakanthan JM, Yuan J, Fedoriw Y, Bociek RG, Kaiser-Rogers K, Sanmann JN, Montgomery ND.
    Hum Pathol; 2018 Oct 10; 80():192-200. PubMed ID: 29902576
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W, Hu S, Lu X, Young KH, Medeiros LJ.
    Am J Surg Pathol; 2015 Aug 10; 39(8):1132-9. PubMed ID: 25828391
    [Abstract] [Full Text] [Related]

  • 29. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
    Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A.
    Br J Haematol; 2015 Aug 10; 170(4):504-14. PubMed ID: 25907897
    [Abstract] [Full Text] [Related]

  • 30. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
    Sarkozy C, Traverse-Glehen A, Coiffier B.
    Lancet Oncol; 2015 Nov 10; 16(15):e555-e567. PubMed ID: 26545844
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, Tang G, Reddy NM, Medeiros LJ, Lin P.
    Am J Surg Pathol; 2016 Feb 10; 40(2):253-61. PubMed ID: 26448193
    [Abstract] [Full Text] [Related]

  • 33. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC, Maciel-Guerra H, Kucko L, Hirama EJ, Brilhante AD, Quevedo FC, da Cunha IW, Soares FA, Niero-Melo L, Dos Reis PP, Domingues MA.
    Diagn Pathol; 2017 Jan 07; 12(1):3. PubMed ID: 28061782
    [Abstract] [Full Text] [Related]

  • 34. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.
    J Clin Oncol; 2017 Jan 07; 35(1):24-31. PubMed ID: 28034071
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E, Tan LH, Tay K, Lim ST, Tang T, Lee YY, Tan SY.
    Histopathology; 2012 Dec 07; 61(6):1214-8. PubMed ID: 23171357
    [Abstract] [Full Text] [Related]

  • 38. Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.
    Lucioni M, Pescia C, Bonometti A, Fraticelli S, Moltrasio C, Ramponi A, Riboni R, Roccio S, Ferrario G, Arcaini L, Goteri G, Berti E, Paulli M.
    Hum Pathol; 2021 May 07; 111():1-9. PubMed ID: 33548250
    [Abstract] [Full Text] [Related]

  • 39. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
    Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW.
    Clin Lymphoma Myeloma Leuk; 2015 Jun 07; 15(6):341-8. PubMed ID: 25656914
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.